Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer.
作者信息
Nunes-Xavier Caroline E
机构信息
Biobizkaia Health Research Institute, Spain; Institute for Cancer Research, Oslo University Hospital, Norway; CIBERER, ISCIII, Spain.
出版信息
Transl Oncol. 2024 Sep;47:102005. doi: 10.1016/j.tranon.2024.102005. Epub 2024 May 23.
Abstract
摘要
相似文献
1
Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer.社论：共抑制性免疫检查点蛋白作为癌症的生物标志物和治疗靶点
Transl Oncol. 2024 Sep;47:102005. doi: 10.1016/j.tranon.2024.102005. Epub 2024 May 23.
2
Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care.开拓新领域：癌症治疗、生物标志物及药物递送系统中的共抑制性免疫检查点蛋白
Transl Oncol. 2023 Dec;38:101794. doi: 10.1016/j.tranon.2023.101794. Epub 2023 Oct 9.
3
Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.早期乳腺癌患者的系统性免疫失调与可溶性共抑制和共刺激免疫检查点分子的血浆水平降低有关。
Front Immunol. 2022 May 23;13:823842. doi: 10.3389/fimmu.2022.823842. eCollection 2022.
4
Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy.共抑制分子的泛癌分析揭示了它们在免疫治疗中的潜在预后和临床价值。
Front Immunol. 2025 Mar 24;16:1544104. doi: 10.3389/fimmu.2025.1544104. eCollection 2025.
5
Emerging druggable targets for immune checkpoint modulation in cancer immunotherapy: the iceberg lies beneath the surface.癌症免疫治疗中免疫检查点调节的新兴可用药靶：冰山在水面之下。
Apoptosis. 2024 Dec;29(11-12):1879-1913. doi: 10.1007/s10495-024-02022-8. Epub 2024 Oct 1.
6
Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.经体外靶向免疫检查点分子减少胆管癌中的免疫抑制性肿瘤微环境。
J Hepatol. 2019 Oct;71(4):753-762. doi: 10.1016/j.jhep.2019.05.026. Epub 2019 Jun 11.
7
Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.新型免疫检查点靶标在卵巢癌肿瘤微环境中的分布：动态景观。
Gynecol Oncol. 2021 Jan;160(1):279-284. doi: 10.1016/j.ygyno.2020.09.045. Epub 2020 Nov 6.
8
Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.操纵免疫系统以战胜癌症：聚焦于 T 细胞抑制性检查点分子。
Curr Med Chem. 2020;27(15):2402-2448. doi: 10.2174/0929867325666181106114421.
9
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.原发性肝癌肿瘤微环境中的免疫抑制检查点相互作用。
Br J Cancer. 2022 Jan;126(1):10-23. doi: 10.1038/s41416-021-01453-3. Epub 2021 Aug 16.
10
Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer.免疫检查点神经纤毛蛋白作为胰腺癌的新型生物标志物和治疗靶点
Cancers (Basel). 2023 Apr 10;15(8):2225. doi: 10.3390/cancers15082225.
本文引用的文献
1
Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer.靶向PD-1/PD-L1轴的肽基抑制剂：癌症的潜在免疫疗法
Transl Oncol. 2024 Apr;42:101892. doi: 10.1016/j.tranon.2024.101892. Epub 2024 Feb 14.
2
Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma.转化生长因子-β1和可溶性共抑制性免疫检查点作为基底细胞癌患者免疫抑制的潜在驱动因素。
Transl Oncol. 2024 Apr;42:101867. doi: 10.1016/j.tranon.2023.101867. Epub 2024 Feb 2.
3
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations.抗PD-1/PD-L1疗法治疗结直肠癌：临床意义与未来考量
Transl Oncol. 2024 Feb;40:101851. doi: 10.1016/j.tranon.2023.101851. Epub 2023 Dec 1.
4
Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC.免疫肿瘤学通路的基因表达谱（GEP）作为晚期非小细胞肺癌（NSCLC）中检查点抑制剂反应的预测指标
Transl Oncol. 2024 Jan;39:101818. doi: 10.1016/j.tranon.2023.101818. Epub 2023 Oct 31.
5
B7-H3/CD276 and small-cell lung cancer: What's new?B7-H3/CD276与小细胞肺癌：有哪些新进展？
Transl Oncol. 2024 Jan;39:101801. doi: 10.1016/j.tranon.2023.101801. Epub 2023 Oct 20.
6
The co-inhibitory immune checkpoint proteins B7-H1(PD-L1) and B7-H4 in high grade glioma: From bench to bedside.高级别胶质瘤中的共抑制性免疫检查点蛋白B7-H1（PD-L1）和B7-H4：从实验台到临床应用
Transl Oncol. 2024 Jan;39:101793. doi: 10.1016/j.tranon.2023.101793. Epub 2023 Oct 14.
7
Activation of immune evasion machinery is a part of the process of malignant transformation of human cells.免疫逃逸机制的激活是人类细胞恶性转化过程的一部分。
Transl Oncol. 2024 Jan;39:101805. doi: 10.1016/j.tranon.2023.101805. Epub 2023 Oct 14.
8
Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care.开拓新领域：癌症治疗、生物标志物及药物递送系统中的共抑制性免疫检查点蛋白
Transl Oncol. 2023 Dec;38:101794. doi: 10.1016/j.tranon.2023.101794. Epub 2023 Oct 9.
9
Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies.肿瘤突变负荷在肺癌患者对免疫检查点抑制疗法的预后及反应中的作用
Transl Oncol. 2023 Dec;38:101788. doi: 10.1016/j.tranon.2023.101788. Epub 2023 Sep 28.
10
Hopes on immunotherapy targeting B7-H3 in neuroblastoma.针对神经母细胞瘤中B7-H3的免疫疗法的希望。
Transl Oncol. 2023 Jan;27:101580. doi: 10.1016/j.tranon.2022.101580. Epub 2022 Oct 31.
Zotero 插件